Compile Data Set for Download or QSAR
maximum 50k data
Found 36 Enz. Inhib. hit(s) with all data for entry = 9724
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484071((S)-1-((R)-8-(1H- pyrrolo[3,2-b]pyridin-6- ylsulfo...)
Affinity DataIC50:  7.00E+3nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484061((2S)-1-(3-(1- fluoroethylsulfonyl) phenoxy)-3-((R)...)
Affinity DataIC50:  1.02E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484073((S)-1-((R)-8-(1H- pyrrolo[3,2-b]pyridin-6- ylsulfo...)
Affinity DataIC50:  1.12E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484058((S)-1-((S)-8-(4'- (aminomethyl)-5- methoxybiphenyl...)
Affinity DataIC50:  1.16E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484059((S)-1-((S)-8-(4'- (aminomethyl)-4- ethoxybiphenyl-...)
Affinity DataIC50:  1.50E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484060((S)-1-((S)-8-(4'- (aminomethyl)-4- ethoxybiphenyl-...)
Affinity DataIC50:  1.66E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484076(3-((R)-3-((S)-3-(3- (cyclopropylsulfonyl) phenoxy)...)
Affinity DataIC50:  1.73E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484050((S)-1-((S)-8-(4'- (aminomethyl)-4- ethoxybiphenyl-...)
Affinity DataIC50:  1.73E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484051((S)-1-((R)-8-(4'- (aminomethyl)-4- fluorobiphenyl-...)
Affinity DataIC50:  1.75E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484048((S)-1-(3-(cyclopropyl- sulfonyl)phenoxy)- 3-((R)-8...)
Affinity DataIC50:  1.75E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484073((S)-1-((R)-8-(1H- pyrrolo[3,2-b]pyridin-6- ylsulfo...)
Affinity DataIC50:  1.78E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484057((S)-1-((S)-8-(4'- (aminomethyl)-6- methoxybiphenyl...)
Affinity DataIC50:  1.79E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484066((S)-1-((S)-8-(4'- ((butylamino)methyl) biphenyl-3-...)
Affinity DataIC50:  1.84E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484047((S)-1-(3-(1- (hydroxymethyl) cyclopropylsulfonyl) ...)
Affinity DataIC50:  1.88E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484070((S)-1-(3-(1- (hydroxymethyl) cyclopropylsulfonyl) ...)
Affinity DataIC50:  2.04E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484063((S)-1-(3-(1- (hydroxymelhyl) cyclopropylsulfonyl) ...)
Affinity DataIC50:  2.11E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484049((S)-1-((R)-8-(4'- (aminomethyl)-4- ethoxybiphenyl-...)
Affinity DataIC50:  2.11E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484075(1-ethyl-8-fluoro-3-((R)- 3-((S)-2-hydroxy-3-(3- (m...)
Affinity DataIC50:  2.18E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484053((S)-1-((S)-8-(4'-(2- aminoethyl)biphenyl-3- ylsulf...)
Affinity DataIC50:  2.24E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484052((S)-1-((R)-8-(4'-(1- aminocyclopropyl)-6- methoxyb...)
Affinity DataIC50:  2.50E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484045((S)-1-(3-(2- hydroxyethylsulfonyl) phenoxy)-3-(R)-...)
Affinity DataIC50:  2.51E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484054((S)-1-((S)-8-(4'-(2- aminoethyl)biphenyl-3- ylsulf...)
Affinity DataIC50:  2.62E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484069(3-((R)-3-((S)-3-(3- (cyclopropylsulfonyl) phenoxy)...)
Affinity DataIC50:  2.65E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484065((S)-l-(3-(l- (hydroxymethyl) cyclopropylsulfonyl) ...)
Affinity DataIC50:  2.78E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484055((S)-1-((R)-8-(4'-(1- aminocyclopropyl)-6- fluorobi...)
Affinity DataIC50:  2.84E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484077(3-((R)-3-((S)-3-(3- (cyclopropylsulfonyl) phenoxy)...)
Affinity DataIC50:  2.89E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484078(3-((R)-3-((S)-3-(3- (cyclopropylsulfonyl) phenoxy)...)
Affinity DataIC50:  2.95E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484079(1-ethyl-8-fluoro-3-((R)- 3-((S)-2-hydroxy-3-(3- (i...)
Affinity DataIC50:  3.00E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484062((S)-1-((S)-8-(4'-((tert- butylamino(methyl) biphen...)
Affinity DataIC50:  3.17E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484056((S)-1-((S)-8-(4'-(1- aminocyclopropyl)-6- methoxyb...)
Affinity DataIC50:  3.31E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484044((2S)-1-(3-(2- hydroxyethylsulfonyl) phenoxy)-3-(8-...)
Affinity DataIC50:  3.33E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484067((S)-1-(3-(1- (hydroxymethyl) cyclopropylsulfonyl) ...)
Affinity DataIC50:  3.35E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484064((S)-1-((S)-8-(4'- (azetidin-1- ylmethyl)biphenyl-3...)
Affinity DataIC50:  3.50E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484072(1-ethyl-3-((R)-3-((S)-2- hydroxy-3-(3- (methylsulf...)
Affinity DataIC50:  3.77E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484046(2-(3-((S)-2-hydroxy-3- ((R)-8-(quinolin-3- ylsulfo...)
Affinity DataIC50:  5.32E+4nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBeta-3 adrenergic receptor(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM484068(1-ethyl-3-((S)-3-((R)-2- hydroxy-3-(3- (methylsulf...)
Affinity DataIC50:  1.07E+5nMAssay Description:Compounds were dissolved and serially diluted (5-fold) in DMSO to generate a 10-point dose response stock. The stock was then diluted 100-fold in ass...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent